keyword
MENU ▼
Read by QxMD icon Read
search

hcv clearance

keyword
https://www.readbyqxmd.com/read/29773081/long-term-familial-mediterranean-fever-remission-on-successful-hepatitis-c-virus-treatment-in-a-patient-not-responding-to-colchicine-a-case-report
#1
Manik Gemilyan, Gagik Hakobyan, Susanna Ananyan
BACKGROUND: Familial Mediterranean fever is an autosomal recessive disorder characterized by periodic febrile attacks of aseptic serositis and/or arthritis. The main treatment is colchicine which prevents attacks in the majority of patients except for a group of colchicine-resistant cases. Chronic hepatitis C is a viral infection causing chronic inflammation of liver tissue (hepatitis) which ultimately progresses to fibrosis and liver cirrhosis with a high chance of hepatocellular carcinoma...
May 18, 2018: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29769038/impact-of-new-daa-therapy-on-real-clinical-practice-a-multicenter-region-wide-cohort-study
#2
Simone Lanini, Paola Scognamiglio, Alessandra Mecozzi, Lorella Lombardozzi, Vincenzo Vullo, Mario Angelico, Antonio Gasbarrini, Gloria Taliani, Adolfo Francesco Attili, Carlo Federico Perno, Adriano De Santis, Vincenzo Puro, Fabio Cerqua, Gianpiero D'Offizi, Adriano Pellicelli, Orlando Armignacco, Francesco Saverio Mennini, Massimo Siciliano, Enrico Girardi, Vincenzo Panella, Giuseppe Ippolito
BACKGROUND: Management of chronic hepatitis C (CHC) has significantly accelerated in the last few years. Currently, second generation direct acting antivirals (DAAs) promise clearance of infection in most of patients. Here we present the results of the first analysis carried out on data of Lazio clinical network for DAAs. METHODS: The study was designed as a multicenter cohort: a) to assess the evolution of treatment during the first 24 months of the activity of the Clinical Network; b) to report overall efficacy of treatments; c) to analyze potential factors associated with lack of virological response at 12 weeks after therapy (SVR12); d) to evaluate the variation of ALT at baseline and 12 weeks after therapy in those who achieved SVR12 in comparison to those who did not...
May 16, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29765541/the-effect-of-antiviral-therapy-on-serum-lipid-profiles-in-chronic-hepatitis-c
#3
Batbold Batsaikhan, Ching-I Huang, Ming-Lun Yeh, Chung-Feng Huang, Nei-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang, Jin-Ching Lee, Chia-Yen Dai
Background: Low lipid profile is associated with hepatitis C virus (HCV) infection. Chronic HCV infection is the main cause of liver injury and serum lipid levels during antiviral treatment. We aimed to evaluate the effect of antiviral treatment on the change of lipid profiles during HCV treatment. Methods: Total 863 patients who complete the interferon-based therapy in Kaohsiung Medical University Hospital were included in this study. The lipid profile measured and evaluated in baseline and after 6 months of the treatment...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29746888/nearly-neutral-evolution-in-ifnl3-gene-retains-the-immune-function-to-detect-and-clear-the-viral-infection-in-hcv
#4
Pratichi Singh, J Febin Prabhu Dass
IFNL3 gene plays a crucial role in immune defense against viruses. It induces the interferon stimulated genes (ISGs) with antiviral properties by activating the JAK-STAT pathway. In this study, we investigated the evolutionary force involved in shaping the IFNL3 gene to perform its downstream function as a regulatory gene in HCV clearance. We have selected 25 IFNL3 coding sequences with human gene as a reference sequence and constructed a phylogeny. Furthermore, rate of variation, substitution saturation test, phylogenetic informativeness and differential selection were also analysed...
May 7, 2018: Progress in Biophysics and Molecular Biology
https://www.readbyqxmd.com/read/29744934/modelling-how-reversal-of-immune-exhaustion-elicits-cure-of-chronic-hepatitis-c-after-the-end-of-treatment-with-direct-acting-antiviral-agents
#5
Subhasish Baral, Rahul Roy, Narendra M Dixit
A fraction of chronic hepatitis C patients treated with direct-acting antivirals (DAAs) achieved sustained virological responses (SVR), or cure, despite having detectable viremia at the end of treatment (EOT). This observation, termed EOT+ /SVR, remains puzzling and precludes rational optimization of treatment durations. One hypothesis to explain EOT+ /SVR, the immunologic hypothesis, argues that the viral decline induced by DAAs during treatment reverses the exhaustion of cytotoxic T lymphocytes (CTLs), which then clear the infection after treatment...
May 9, 2018: Immunology and Cell Biology
https://www.readbyqxmd.com/read/29743799/advances-in-hcv-and-cryoglobulinemic-vasculitis-in-the-era-of-daas-are-we-at-the-end-of-the-road
#6
REVIEW
Chalermrat Bunchorntavakul, Robert Mitrani, K Rajender Reddy
Hepatitis C Virus (HCV)-related Mixed Cryoglobulinemia (MC) is a unique condition with complex pathogenesis that involves HCV antigen-driven B-lymphocyte clonal proliferation and mutagenesis. Clinical spectrum of MC ranges from asymptomatic state to clinically-apparent vasculitis involving multiple organs. In the era of Direct-Acting Antiviral (DAA) therapy, patients with HCV-related MC achieve high rates of viral clearance that is commonly accompanied by an improvement in clinical symptoms as well as immunological profiles...
March 2018: Journal of Clinical and Experimental Hepatology
https://www.readbyqxmd.com/read/29742812/binding-of-free-and-immune-complex-associated-hepatitis-c-virus-to-erythrocytes-is-mediated-by-the-complement-system
#7
Kazi Abdus Salam, Richard Y Wang, Teresa Grandinetti, Valeria De Giorgi, Harvey J Alter, Robert D Allison
Erythrocytes bind circulating immune complexes (IC) and facilitate IC clearance from the circulation. Chronic hepatitis C virus (HCV) infection is associated with IC-related disorders. In this study we investigated the kinetics and mechanism of HCV and HCV-IC binding to and dissociation from erythrocytes. Cell culture-produced HCV was mixed with erythrocytes from healthy blood donors and erythrocyte-associated virus particles were quantified. Purified complement proteins, complement-depleted serum, and complement receptor antibodies were used to investigate complement-mediated HCV-erythrocyte binding...
May 9, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29739095/distribution-of-il28b-rs12979860-and-rs8099917-genotypes-in-patients-with-chronic-hepatitis-c-virus-infection-in-tianjin-china
#8
Kunyan Qiao, Congdoanh Trieu, Zhixiao Huo, Yanan Du, Wei Hou
BACKGROUND: Two single-nucleotide polymorphisms (SNPs) rs12979860 (C/T) and rs8099917 (T/G), near the interleukin 28B (IL28B, also known as IFN lambda-3, IFNL3) gene, have a strong association with both spontaneous and treatment-induced hepatitis C virus (HCV) clearance. IL28B polymorphisms have shown a marked differential distribution with regional and ethnic variation. The study aimed to investigate the distribution of IL28B rs12979860 and rs8099917 genotypes in patients with chronic hepatitis C (CHC) in Tianjin, China...
April 1, 2018: Clinical Laboratory
https://www.readbyqxmd.com/read/29731972/kir2dl2-combined-with-hla-c1-confers-risk-of-hepatitis-c-virus-related-hepatocellular-carcinoma-in-younger-patients
#9
Hiromi Saito, Takeji Umemura, Satoru Joshita, Tomoo Yamazaki, Naoyuki Fujimori, Takefumi Kimura, Michiharu Komatsu, Akihiro Matsumoto, Eiji Tanaka, Masao Ota
Killer cell immunoglobulin-like receptors (KIRs) are involved in the activation and inhibition of natural killer cells. Although combinations of KIRs and HLA have been associated with spontaneous and treatment-induced clearance of hepatitis C virus (HCV) infection, their roles are not fully understood in the context of hepatocellular carcinoma (HCC) development. We enrolled 787 consecutive patients with chronic HCV infection, which included 174 cases of HCC, and 325 healthy subjects to clarify the involvement of HLA-Bw and C, KIRs, and major histocompatibility complex class I chain-related gene A (MICA) gene polymorphisms (rs2596542 and rs1051792) in chronic HCV infection and HCV-related HCC...
April 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29722275/eliminating-hiv-hcv-co-infection-in-gay-and-bisexual-men-is-it-achievable-through-scaling-up-treatment
#10
Rachel Sacks-Davis, Alisa E Pedrana, Nick Scott, Joseph S Doyle, Margaret E Hellard
Broad availability of direct-acting antiviral therapy for hepatitis C virus (HCV) raises the possibility that HCV prevalence and incidence can be reduced through scaling-up treatment, leading to the elimination of HCV. High rates of linkage to HIV care among HIV-infected gay and bisexual men may facilitate high uptake of HCV treatment, possibly making HCV elimination more achievable in this group. Areas covered: This review covers HCV elimination in HIV-infected gay and bisexual men, including epidemiology, spontaneous clearance and long term sequelae in the absence of direct-acting antiviral therapy; direct-acting antiviral therapy uptake and effectiveness in this group; HCV reinfection following successful treatment; and areas for further research...
May 3, 2018: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/29720863/hepatitis-b-and-c-coinfection-in-a-real-life-setting-viral-interactions-and-treatment-issues
#11
Nikolaos Papadopoulos, Maria Papavdi, Anna Pavlidou, Dimitris Konstantinou, Hariklia Kranidioti, George Kontos, John Koskinas, George V Papatheodoridis, Spilios Manolakopoulos, Melanie Deutsch
Background: Only limited data concerning hepatitis B (HBV) and C viruses (HCV) coinfection are available. Direct-acting antivirals (DAAs) may be more effective for HCV clearance than interferon (IFN)-based regimens with a risk of HBV reactivation. Methods: We retrospectively enrolled 40 HBV/HCV-coinfected patients to evaluate their clinical profile and treatment outcomes. Results: Chronic dual infection was present in 25/40 (62.5%) patients, acute HCV superinfection in 5/40 (12...
May 2018: Annals of Gastroenterology: Quarterly Publication of the Hellenic Society of Gastroenterology
https://www.readbyqxmd.com/read/29707079/prevalence-of-hepatitis-b-reactivation-among-chinese-individuals-with-chronic-hepatitis-c-treated-with-pan-oral-direct-acting-antivirals
#12
Shou-Wu Lee, Teng-Yu Lee, Sheng-Shun Yang, Yen-Chun Peng, Hong-Zen Yeh, Chi-Sen Chang
Background: Clearance of hepatitis C virus (HCV) has been reported to induce the reactivation of hepatitis B virus (HBV). The aim of this study was to investigate the rate of HBV reactivation in HCV-infected Chinese patients who received treatment with pan-oral direct-acting antivirals (DAAs). Methods: Data from HCV subjects receiving oral DAA therapy were retrospectively collected from October 2015 to May 2017. Patients who were seropositive for HBsAg or anti-HBc were enrolled...
April 2018: Gastroenterology Research
https://www.readbyqxmd.com/read/29705123/the-association-of-ccl3-and-ccl4-polymorphisms-with-hcv-clearance-in-chinese-han-population
#13
Mei Liu, Ming Yue, Yinan Yao, Feng Zang, Lingyun Zhuo, Jingjing Wu, Xueshan Xia, Yue Feng, Rongbin Yu, Peng Huang
AIM: To explore the association of CCL3 (rs1063340) and CCL4 (rs1049807) polymorphisms with hepatitis C virus (HCV) clearance and sustained virologic response (SVR). METHODS: Two populations were enrolled in the current study; one was a general population including 1585 untreated individuals, with HCV infection and the other was a treatment population comprising 353 HCV-infected patients treated with pegylated interferon-α and ribavirin (pegIFN-α/RBV). Two single nucleotide polymorphisms (SNPs) were genotyped, and the relationship between HCV clearance and treatment outcome was analysed...
April 26, 2018: Gene
https://www.readbyqxmd.com/read/29704252/baseline-intrahepatic-and-peripheral-innate-immunity-are-associated-with-hepatitis-c-virus-clearance-during-daa-therapy
#14
Hawwa Alao, Maggie Cam, Chithra Keembiyehetty, Fang Zhang, Elisavet Serti, Daniel Suarez, Heiyoung Park, Nicolaas H Fourie, Elizabeth C Wright, Wendy A Henderson, Qisheng Li, T Jake Liang, Barbara Rehermann, Marc G Ghany
OBJECTIVE: Hepatitis C virus (HCV) infection induces interferon-stimulated genes (ISGs) and downstream innate immune responses. This study investigated whether baseline and on-treatment differences in these responses predict response versus virological breakthrough during therapy with direct-acting antivirals (DAA). METHODS: Thirteen HCV genotype 1b-infected patients who had previously failed a course of peginterferon/ribavirin were re-treated with asunaprevir/daclatasvir for 24 weeks...
April 27, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29703961/genetic-variants-in-chemokine-cc-subfamily-genes-influence-hepatitis-c-virus-viral-clearance
#15
Yinan Yao, Ming Yue, Feng Zang, Mei Liu, Haozhi Fan, Lingyun Zhuo, Jingjing Wu, Xueshan Xia, Yue Feng, Peng Huang, Rongbin Yu
Chemokine genes may influence both hepatitis C virus (HCV) spontaneous clearance in acute infection and treatment response in chronic infection. We conducted this study to evaluate whether the genetic variants in several CC family genes influence HCV spontaneous clearance and treatment response. The current research genotyped eight SNPs, including CCR1 rs3733096, rs13096371, CCR5 rs746492, rs1800874, CCL3 rs1130371, CCL5 rs3817656, CCL8 rs1133763, CCL14 rs854625, to explore their associations with HCV spontaneous clearance and response to treatment in two populations...
April 27, 2018: Journal of Human Genetics
https://www.readbyqxmd.com/read/29703495/can-broadly-neutralizing-monoclonal-antibodies-lead-to-a-hepatitis-c-virus-vaccine
#16
REVIEW
Valerie J Kinchen, Andrea L Cox, Justin R Bailey
While licensed vaccines elicit protective antibody responses against a variety of viral infections, an effective vaccine for hepatitis C virus (HCV) has remained elusive. The extraordinary genetic diversity of HCV and the ability of the virus to evade the immune response have hindered vaccine development efforts. However, recent studies have greatly expanded the number of well characterized broadly neutralizing human monoclonal antibodies (bNAbs) against HCV. These bNAbs target relatively conserved HCV epitopes, prevent HCV infection in animal models, and are associated with spontaneous clearance of human HCV infection...
April 24, 2018: Trends in Microbiology
https://www.readbyqxmd.com/read/29695616/abundance-of-phase-i-and-ii-drug-metabolizing-enzymes-in-alcoholic-and-hepatitis-c-cirrhotic-livers-a-quantitative-targeted-proteomics-study
#17
Bhagwat Prasad, Deepak Kumar Bhatt, Katherine Johnson, Revathi Chapa, Xiaoyan Chu, Laurent Salphati, Guangqing Xiao, Caroline Lee, Cornelis Eca Hop, Anita Mathias, Yurong Lai, Mingxiang Liao, W Griffith Humphreys, Sean C Kumer, Jashvant D Unadkat
To predict the impact of liver cirrhosis on hepatic drug clearance using physiologically based pharmacokinetic (PBPK) modeling, we compared the protein abundance of various Phase I and Phase II drug metabolizing enzymes (DMEs) in S9 fractions of alcoholic (n=27) or hepatitis C (HCV, n=30) cirrhotic vs. non-cirrhotic (control) livers (n=25). The S9 total protein content was significantly lower in alcoholic or HCV cirrhotic vs. control livers (i.e., 38.3 ± 8.3, 32.3 ± 12.8 vs. 51.1 ± 20.7 mg/g liver, respectively)...
April 25, 2018: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/29694720/pharmacokinetics-and-drug-interactions-of-medications-used-to-treat-hepatitis-c-virus-infection-in-the-setting-of-chronic-kidney-disease-and-kidney-transplantation
#18
REVIEW
Guillermo A Ortiz, Hirsh D Trivedi, Claudia Nader
Hepatitis C infection in patients with chronic kidney disease or kidney transplant carries higher morbidity and mortality compared to noninfected patients. Historically, patients with advanced kidney disease and kidney transplant recipients were undertreated given the multiple adverse effects and limited efficacy of interferon-based therapies for chronic hepatitis C. The development of direct-acting antivirals in the past few years has opened an unprecedented opportunity for treating these populations. However, the impaired renal clearance of some of these medications in patients with kidney disease, and the potential interactions of antiviral therapies with immunosuppressants after kidney transplantation, present some challenges in choosing the proper regimen...
April 2018: Hemodialysis International
https://www.readbyqxmd.com/read/29692313/the-prevalence-of-hepatitis-c-virus-antibody-in-hiv-negative-persons-in-kenya-2007
#19
Kathleen N Ly, Andrea A Kim, Jan Drobenuic, Maja Kodani, Joel M Montgomery, Barry S Fields, Eyasu H Teshale
The prevalence of hepatitis C virus (HCV) infection in the Kenyan population has not been previously determined. We estimated the Kenyan HCV prevalence in HIV-negative persons aged 15-64 years. This is a retrospective cross-sectional study using data from the 2007 Kenya AIDS Indicator Survey-a nationally representative sample of 15,853 persons aged 15-64 years who completed a health interview and provided a blood specimen. Of the 1,091 randomly selected participants, 50 tested positive for HCV antibody using the automated chemiluminescence immunoassay, corresponding to a weighted HCV antibody positivity rate of 4...
April 23, 2018: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/29689122/efficacy-and-safety-of-peginterferon-alfa-2a-40kd-in-children-with-chronic-hepatitis-b-the-peg-b-active-study
#20
Stefan Wirth, Hongfei Zhang, Winita Hardikar, Kathleen B Schwarz, Etienne Sokal, Weibo Yang, Huimin Fan, Vyacheslav Morozov, Qing Mao, Hong Deng, Yang Huang, Lei Yang, Nicolas Frey, Clare Nasmyth-Miller, Vedran Pavlovic, Cynthia Wat
Children with chronic hepatitis B (CHB) represent an area of unmet medical need, due to increased lifetime risk of CHB sequelae and limited therapeutic options compared with adult CHB patients. The PEG-B-ACTIVE (NCT01519960) phase III study evaluated peginterferon (PegIFN) alfa-2a treatment in children aged 3 to <18 years with CHB. A total of 161 hepatitis B e antigen (HBeAg)-positive immune-active patients without advanced fibrosis/cirrhosis were randomized (2:1) to PegIFN alfa-2a (Group A, n = 101) or no treatment (Group B, n = 50); patients with advanced fibrosis were assigned to PegIFN alfa-2a (Group C, n = 10)...
April 24, 2018: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
keyword
keyword
62798
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"